CytomX Therapeutics宣布针对EpCAM的Probody®抗体偶联药物（ADC）CX

- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 - - Initiation of CX-801 Phase 1 clinical study in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma also anticipated in 1H 2024 - SOUTH SAN FRANCISCO, Calif., Jan.

-预计2024年1月1日在EpCAM阳性肿瘤（包括结直肠癌）中启动CX-2051 1期临床研究-预计2024年1月1日在实体瘤（包括黑色素瘤，肾癌和头颈部鳞状细胞癌）中启动CX-801 1期临床研究-加利福尼亚州南旧金山，1月。

24, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) applications for the conditionally activated Probody® therapeutics CX-2051, an EpCAM-directed ADC, and CX-801, a dually-masked version of interferon-alpha 2b.

2024年4月24日（环球新闻网）--条件性激活的局部生物制剂领域的领导者CytomX Therapeutics，Inc.（纳斯达克：CTMX）今天宣布，它已获得美国食品和药物管理局（FDA）的批准，用于条件性激活的Probody®Therapeutics CX-2051（一种EpCAM导向的ADC）和CX-801的研究性新药（IND）申请，干扰素α2b的双重掩盖版本。

CX-2051 has been cleared for the initiation of Phase 1 dose escalation in solid tumors with known EpCAM expression and CX-801 has been cleared for the initiation of Phase 1 dose escalation in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma. Both programs are expected to start Phase 1 studies in the first half of 2024.

CX-2051已被清除用于在已知EpCAM表达的实体瘤中开始1期剂量递增，CX-801已被清除用于在实体瘤（包括黑色素瘤，肾癌和头颈部鳞状细胞癌）中开始1期剂量递增。预计这两个项目将于2024年上半年开始第一阶段研究。

“CX-2051 and CX-801 have the potential to address major unmet needs in oncology and we are excited to advance these programs into Phase 1 clinical studies. CX-2051 is an ADC conjugated to a next-generation topoisomerase-1 inhibitor payload that we believe is tailored to certain EpCAM-expressing tumors, including colorectal cancer,” said Wayne Chu, M.D., chief medical officer of CytomX Therapeutics.

“CX-2051和CX-801有潜力解决肿瘤学中未满足的主要需求，我们很高兴将这些项目推进到第一阶段临床研究。CX-2051是一种与下一代拓扑异构酶-1抑制剂有效载荷结合的ADC，我们认为它是针对某些表达EpCAM的肿瘤（包括结直肠癌）量身定制的，”医学博士Wayne Chu说。，CytomX Therapeutics首席医疗官。

“CX-801 is designed to overcome previous limitations of interferon-directed therapies due to systemic toxicity and establish CX-801 as a cornerstone of combination regimens, including with checkpoint inhibitors, across a wide range of tumor types,” continued Dr. Chu. “The parallel adva.

“CX-801旨在克服以前由于全身毒性而导致的干扰素定向治疗的局限性，并将CX-801确立为多种肿瘤类型联合治疗（包括检查点抑制剂）的基石，”朱博士继续说道。“平行广告。